Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
about
Gene aberrations for precision medicine against lung adenocarcinomaMicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for TreatmentBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerThe minority report: targeting the rare oncogenes in NSCLCPulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits: a reappraisal of mucinous adenocarcinoma and colloid adenocarcinomaMolecular Testing of Lung CancersDiagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer.The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltrationRole and regulation of coordinately expressed de novo purine biosynthetic enzymes PPAT and PAICS in lung cancer.Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patientsIdentification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinomaNRG1 fusion in a French cohort of invasive mucinous lung adenocarcinomaSize of Non-lepidic Invasive Pattern Predicts Recurrence in Pulmonary Mucinous Adenocarcinoma: Morphologic Analysis of 188 Resected Cases with Reappraisal of Invasion Criteria.Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lungClassification of different patterns of pulmonary adenocarcinomas.Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non-Small Cell Lung Cancer Cells.Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options.Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.Primary mucinous adenocarcinoma of the lung: A case report and review of the literature.Gene signature driving invasive mucinous adenocarcinoma of the lung.Pros: the present classification of mucinous adenocarcinomas of the lung.Biology of invasive mucinous adenocarcinoma of the lung.MEK inhibitors under development for treatment of non-small-cell lung cancer.Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.Lung Cancer: Understanding Its Molecular Pathology and the 2015 WHO Classification.Discovery of ERBB3 inhibitors for non-small cell lung cancer (NSCLC) via virtual screening.Frequent NRG1 fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing.
P2860
Q26749348-96CB6930-8166-4231-9D95-5391BA7C35B4Q26752548-815E30E9-86FC-47AC-9ABD-B309D3949CD2Q26851421-9A0A5170-7B30-475B-8A0D-D553AC06848FQ26851636-06CEFF9F-6FE0-4190-A9CD-FD4426F9284EQ33593905-65CEE73E-4583-49F5-B4B7-19CEB6E09F83Q33729715-6EC8C2E7-242D-48C4-9067-9A168F2C6A67Q33737293-1751B657-99A0-4103-87A5-C0A9905A4384Q33898524-78374AD5-9265-483C-B892-5E278FD86E8EQ34762165-FB16F8A6-53B9-4248-A955-BA82C0655BFEQ36096044-4810A2BC-A277-46C5-B204-C4F81C39A7DAQ36413817-D87C010F-F5DB-44E5-B492-EA3AFF81BFE9Q36414207-9782A83E-B6B7-44A4-A747-D6C4431D5BB9Q36544077-0CC64FC4-0E38-4856-838D-2153A9EC659BQ37392650-10AF1175-25F0-4653-B1DE-FABEC16CD125Q37577906-BDE259DD-41D1-4EC6-A9F6-AFD839C7B16DQ37607959-91E1883E-E032-4B3E-9FBD-C4092E3219BBQ37688390-2E5811BF-B4A1-428B-9D52-3F782DB5AA32Q38574971-9CAA6E41-FA3F-4C7C-A5E0-8D2BA0AB73CDQ38785003-820DC6E0-EE77-4ACD-857C-7453B50D0CD4Q38825099-C8A5C6C1-80ED-454A-8249-08335706B2B4Q39172334-1CEC81EA-066E-42D9-BC61-A37052A59DE6Q40542208-C23AE278-50A9-4295-A2A6-6D3D6C1021C4Q41621426-6080067D-3DA9-47A4-8351-830C69E69D3FQ42293061-8BD583DF-F2F9-45FA-B724-6EA87EE51AF3Q42354098-FF0CF307-A117-4FAB-8DE1-086C4E312958Q43874020-E472467D-D761-4902-A921-5851F65B6D27Q47318847-18EF83F5-E265-492C-B5FF-F7A1737D3F58Q47601932-C5130243-8C0F-4A05-998E-30879339F5A0Q48649855-0D533050-ACBD-4090-82AC-E97BFC57E6EBQ50143858-DCDC4ADA-DCB0-4596-BEC2-14C28AE8DA32Q50852401-E3E1FC3F-3CD5-4ECE-A1C6-07DF44CDF083Q52668218-A6A9F130-A3CE-4D1A-8D2D-BD9EBC8622F1Q55479808-130F8BDD-8D4D-4B64-B18D-96899C344C6D
P2860
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@en
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@nl
type
label
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@en
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@nl
prefLabel
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@en
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
@nl
P2093
P1476
Druggable oncogene fusions in invasive mucinous lung adenocarcinoma
@en
P2093
Aaron J Schetter
Curtis C Harris
Hiromi Sakamoto
Hiroshi Nokihara
Hitoshi Ichikawa
Jun Yokota
Kazuki Yasuda
Koh Furuta
Koji Tsuta
Kouya Shiraishi
P304
P356
10.1158/1078-0432.CCR-14-0107
P407
P577
2014-04-11T00:00:00Z